In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume.

The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

Vaccine series completion for rotavirus, DTaP, PCV at 12 months was highest in January 2020 and remained lower in October 2023.

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

HealthDay News — The federal government is clawing back $11.4 billion in COVID funding, a move that could affect local and state public health efforts across the country. The US Department of Health ...

HealthDay News — Preliminary data released this month by the US Centers for Disease Control and Prevention indicate that more than 10,300 tuberculosis (TB) cases were reported last year, representing ...

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.

HealthDay News — Dozens of research projects focused on LGBTQ health have been canceled by the US government, alarming scientists who say the move will harm public health and slow scientific progress.

Hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.